

XTL BIOPHARMACEUTICALS LTD  
Form 4  
March 19, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
EDELMAN JOSEPH

2. Issuer Name and Ticker or Trading Symbol  
XTL BIOPHARMACEUTICALS LTD [XTLB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
03/10/2008

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
 10% Owner  
\_\_\_\_ Other (specify below)

PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

NEW YORK, NY 10022

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares <sup>(1)</sup>	03/10/2008		P		470,000	A	\$ 3.2456	53,117,820	I	see footnote (2)
Ordinary Shares <sup>(1)</sup>	03/10/2008		P		470,000	A	\$ 3.15	53,587,820	I	see footnote (2)
Ordinary Shares <sup>(1)</sup>	03/10/2008		P		394,800	A	\$ 3.2765	5,398,260	I	see footnote (2)

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 4

Ordinary Shares <sup>(1)</sup>	03/11/2008	P	470,000	A	\$ 3.3117	54,452,620	I	see footnote <u>(2)</u>
Ordinary Shares <sup>(1)</sup>	03/11/2008	P	107,100	A	\$ 3.3048	54,559,720	I	see footnote <u>(2)</u>
Ordinary Shares <sup>(1)</sup>	03/12/2008	P	141,000	A	\$ 3.3661	54,700,720	I	see footnote <u>(2)</u>
Ordinary Shares <sup>(1)</sup>	03/12/2008	P	272,600	A	\$ 3.3501	54,973,320	I	see footnote <u>(2)</u>
Ordinary Shares <sup>(1)</sup>	03/13/2008	P	138,180	A	\$ 3.3803	55,111,500	I	see footnote <u>(2)</u>
Ordinary Shares <sup>(1)</sup>	03/13/2008	P	94,000	A	\$ 3.3733	55,205,500	I	see footnote <u>(1)</u>
Ordinary Shares <sup>(1)</sup>	03/10/2008	P	30,000	A	\$ 3.2456	2,811,600	I	see footnote <u>(3)</u>
Ordinary Shares <sup>(1)</sup>	03/10/2008	P	30,000	A	\$ 3.15	2,841,600	I	see footnote <u>(3)</u>
Ordinary Shares <sup>(1)</sup>	03/10/2008	P	25,200	A	\$ 3.2765	2,866,800	I	see footnote <u>(3)</u>
Ordinary Shares <sup>(1)</sup>	03/11/2008	P	30,000	A	\$ 3.3117	2,896,800	I	see footnote <u>(3)</u>
Ordinary Shares <sup>(1)</sup>	03/11/2008	P	11,900	A	\$ 3.3048	2,908,700	I	see footnote <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying	8. Price of Derivative Security	9. Number of Derivative Securities
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	--------------	--	-----------------------------------	---------------------------------	------------------------------------

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	Securities (Instr. 3 and 4)	(Instr. 5)	Beneficial Owner Following Transaction (Instr. 3)
					V	(A)	(D)	
				Date Exercisable		Expiration Date	Title	Amount or Number of Shares

# Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

EDELMAN JOSEPH  
 PERCEPTIVE ADVISORS LLC  
 499 PARK AVENUE, 25TH FLOOR  
 NEW YORK, NY 10022

X

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD  
 C/O PERCEPTIVE ADVISORS LLC  
 499 PARK AVENUE, 25TH FLOOR  
 NEW YORK, NY 10022

X

PERCEPTIVE ADVISORS LLC  
 499 PARK AVENUE, 25TH FLOOR  
 NEW YORK, NY 10022

X

Cho Michael  
 PERCEPTIVE ADVISORS LLC  
 499 PARK AVENUE, 25TH FLOOR  
 NEW YORK, NY 10022

X

Bradley Scott  
 PERCEPTIVE ADVISORS LLC  
 499 PARK AVENUE, 25TH FLOOR  
 NEW YORK, NY 10022

X

## Signatures

/s/ JOSEPH EDELMAN                      03/17/2008

\_\_Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 4

This Form 4 is being filed by Joseph Edelman, Michael Cho, Scott Bradley, Perceptive Life Science Master Fund Ltd. ("Master Fund") and Perceptive Advisors LLC ("Advisors").

- (2) This transaction was effected through the Master Fund. Mr. Edelman is the managing member of Advisors, which in turn serves as the investment manager of Master Fund. Mr. Edelman and Mr. Bradley share dispositive power over 1,010,000 of such shares and Mr. Edelman and Mr. Cho share dispositive power of 2,516,450 of such shares. Mr. Edelman has sole voting and dispositive power over the remainder of such shares. In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the Issuer's securities held by Master Fund is reported herein. Each of Mr. Edelman, Mr. Cho, Mr. Bradley and Advisors disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary therein, and this report shall not be deemed an admission that Mr. Edelman, Mr. Cho, Mr. Bradley and Advisors is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

- (3) This transaction was effected through an account at First New York Trading, LLC. Mr. Edelman and Mr. Cho share dispositive power over 279,570 of such shares and Mr. Edelman has sole voting and dispositive power over the remainder of such shares. Mr. Edelman and Mr. Cho each disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or Mr. Cho is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Mr. Bradley disclaims beneficial ownership over all such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.